Barclays analyst Gena Wang lowered the firm’s price target on Moderna (MRNA) to $25 from $31 and keeps an Equal Weight rating on the shares following the Q3 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Moderna Reports Q3 2025 Financial Results
- Moderna’s Earnings Call: Balancing Achievements and Challenges
- Moderna’s Strategic Challenges and Opportunities: A Hold Rating Amid Mixed Product Results and Market Uncertainties
- SPY ETF Daily Update, 11/6/2025
- Midday Fly By: Qualcomm reports Q4 beat, Schwab acquires Forge